Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.410
0.00 (0.00%)
At close: Jun 18, 2026, 4:00 PM EDT
4.390
-0.020 (-0.45%)
After-hours: Jun 18, 2026, 7:14 PM EDT
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
285.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Invivyd | 55.87M |
| Zentalis Pharmaceuticals | 26.87M |
| Surrozen | 7.49M |
| Armata Pharmaceuticals | 5.20M |
| Cartesian Therapeutics | 1.78M |
| SAB Biotherapeutics | 114.70K |
IMRX News
- 3 days ago - Immuneering appoints Andrew Gengos as CFO - TheFly
- 3 days ago - Immuneering Appoints Andrew Gengos as Chief Financial Officer - GlobeNewsWire
- 7 days ago - Immuneering Transcript: AGM 2026 - Transcripts
- 7 days ago - Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - GlobeNewsWire
- 17 days ago - Immuneering announces updated clinical data from atebimetinib combination trial - TheFly
- 17 days ago - Immuneering Transcript: Study result - Transcripts
- 17 days ago - Immuneering Press release: Study result - Filings
- 17 days ago - Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO - GlobeNewsWire